Handel Eledon Pharmaceuticals, Inc. - ELDN CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | - | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Nøglestatistikker
| Tidligere luk* | N/A |
| Åben* | N/A |
| 1-Års Ændring* | N/A |
| Dagens Spænd* | N/A |
| 52-Ugers Spænd | 1.90-4.15 |
| Gennemsnitlig Volumen (10 dage) | 40.40K |
| Gennemsnitlig Volumen (3 måneder) | 457.00K |
| Market Cap | 32.47M |
| P/E-forhold | -100.00K |
| Udestående aktier | 13.76M |
| Omsætning | N/A |
| EPS | -2.66 |
| Dividend (Udbytte %) | N/A |
| Beta | 2.13 |
| Næste indtjeningsopgørelse | Mar 30, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|
Eledon Pharmaceuticals, Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| No events scheduled | ||
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Omsætning | |||||
| Totale Driftsudgifter | 36.867 | 18.465 | 16.051 | 14.06 | 13.121 |
| Salgs/Generelle/Admin. Udgifter, Total | 13.132 | 10.052 | 6.056 | 7.243 | 11.099 |
| Forskning & Udvikling | 23.735 | 6.131 | 8.128 | 6.817 | 2.022 |
| Driftsindtægter | -36.867 | -18.465 | -16.051 | -14.06 | -13.121 |
| Renteindkomst (Udgift), Netto Ikke-Drift | |||||
| Netto Indkomst Før Skat | -36.86 | -23.215 | -16.011 | -14.065 | -13.116 |
| Netto Indkomst Efter Skat | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
| Netto Indkomst Før Ekstra Ting | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
| Netto Indkomst | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
| Fortyndet Netto Indkomst | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
| Fortyndet Vægtet Gennemsnit Aktier | 14.8196 | 1.45143 | 0.65558 | 0.50034 | 0.25989 |
| Fortyndet EPS Uden Ekstraordinære Ting | -2.32841 | -15.7162 | -24.4227 | -28.111 | -50.4679 |
| Fortyndet Normaliseret EPS | -2.32841 | -14.6943 | -21.5748 | -28.111 | -50.4679 |
| Andre, Netto | 0.007 | -4.75 | 0.04 | -0.005 | 0.005 |
| Totale Ekstraordinære Ting | 0 | ||||
| Usædvanlig Udgift (Indkomst) | 0 | 2.282 | 1.867 |
| Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 10.598 | 9.283 | 9.859 | 9.385 | 10.506 |
| Salgs/Generelle/Admin. Udgifter, Total | 3.146 | 3.54 | 3.224 | 3.203 | 2.848 |
| Forskning & Udvikling | 7.452 | 5.743 | 6.635 | 6.182 | 7.658 |
| Driftsindtægter | -10.598 | -9.283 | -9.859 | -9.385 | -10.506 |
| Andre, Netto | 0.127 | 0.036 | -0.005 | 0 | 0.003 |
| Netto Indkomst Før Skat | -10.471 | -9.247 | -9.864 | -9.385 | -10.503 |
| Netto Indkomst Efter Skat | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
| Netto Indkomst Før Ekstra Ting | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
| Netto Indkomst | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
| Fortyndet Netto Indkomst | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
| Fortyndet Vægtet Gennemsnit Aktier | 14.2659 | 14.2659 | 14.3307 | 14.8159 | 14.8159 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.73399 | -0.64819 | -0.68831 | -0.59436 | -0.6626 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -0.73399 | -0.64819 | -0.68831 | -0.59436 | -0.6626 |
| Usædvanlig Udgift (Indkomst) | 0 | 0 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 88.346 | 115.63 | 9.971 | 14.276 | 19 |
| Likvider og Kortsigtede Investeringer | 84.833 | 114.195 | 8.791 | 12.972 | 17.233 |
| Likvider & Lignende | 84.833 | 114.195 | 8.791 | 12.972 | 17.233 |
| Kortsigtede Investeringer | |||||
| Prepaid Expenses | 3.479 | 1.287 | 0.881 | 0.674 | 1.697 |
| Other Current Assets, Total | 0.034 | 0.038 | 0.054 | 0.63 | 0.07 |
| Total Assets | 170.548 | 197.185 | 10.931 | 17.026 | 20.892 |
| Property/Plant/Equipment, Total - Net | 0.768 | 0.138 | 0.321 | 0.014 | 0.025 |
| Property/Plant/Equipment, Total - Gross | |||||
| Accumulated Depreciation, Total | |||||
| Other Long Term Assets, Total | 0.4 | 0.383 | 0.639 | 0.869 | 0 |
| Total Current Liabilities | 4.401 | 2.483 | 1.322 | 2.534 | 1.44 |
| Accounts Payable | 1.813 | 1.366 | 0.329 | 0.689 | 0.418 |
| Accrued Expenses | 2.588 | 1.117 | 0.993 | 1.845 | 1.022 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 6.553 | 6.589 | 1.466 | 2.534 | 1.44 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Total Equity | 163.995 | 190.596 | 9.465 | 14.492 | 19.452 |
| Redeemable Preferred Stock | 0 | 0 | 0 | ||
| Common Stock | 0.014 | 0.015 | 0.013 | 0.009 | 0.007 |
| Additional Paid-In Capital | 278.88 | 270.974 | 67.034 | 56.054 | 46.951 |
| Retained Earnings (Accumulated Deficit) | -114.899 | -80.393 | -57.582 | -41.571 | -27.506 |
| Other Equity, Total | |||||
| Total Liabilities & Shareholders’ Equity | 170.548 | 197.185 | 10.931 | 17.026 | 20.892 |
| Total Common Shares Outstanding | 14.3068 | 15.1604 | 0.72047 | 0.52349 | 0.39505 |
| Goodwill, Net | 48.648 | 48.648 | 0 | 1.867 | 1.867 |
| Totale Tilgodehavender, Netto | 0 | 0.11 | 0.245 | ||
| Other Liabilities, Total | 0.4 | 0 | 0.144 | ||
| Intangibles, Net | 32.386 | 32.386 | |||
| Deferred Income Tax | 1.752 | 4.106 | |||
| Total Preferred Shares Outstanding | 0.11427 | 0.10807 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 79.325 | 88.346 | 95.558 | 102.582 | 110.241 |
| Likvider og Kortsigtede Investeringer | 76.677 | 84.833 | 94.041 | 101.133 | 108.579 |
| Likvider & Lignende | 76.677 | 84.833 | 94.041 | 101.133 | 108.579 |
| Totale Tilgodehavender, Netto | 0 | 0 | 0.087 | 0.197 | |
| Prepaid Expenses | 2.631 | 3.479 | 1.506 | 1.351 | 1.439 |
| Other Current Assets, Total | 0.017 | 0.034 | 0.011 | 0.011 | 0.026 |
| Total Assets | 161.378 | 170.548 | 177.17 | 184.305 | 191.682 |
| Property/Plant/Equipment, Total - Net | 0.675 | 0.768 | 0.222 | 0.267 | 0.092 |
| Goodwill, Net | 48.648 | 48.648 | 48.648 | 48.648 | 48.648 |
| Intangibles, Net | 32.386 | 32.386 | 32.386 | 32.386 | 32.386 |
| Other Long Term Assets, Total | 0.344 | 0.4 | 0.356 | 0.422 | 0.315 |
| Total Current Liabilities | 2.958 | 4.401 | 4.046 | 2.677 | 4.206 |
| Accounts Payable | 1.026 | 1.813 | 1.598 | 0.857 | 1.514 |
| Accrued Expenses | 1.932 | 2.588 | 2.448 | 1.82 | 2.692 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 5.06 | 6.553 | 6.422 | 5.784 | 7.811 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 1.752 | 1.752 | 2.331 | 3.017 | 3.605 |
| Total Equity | 156.318 | 163.995 | 170.748 | 178.521 | 183.871 |
| Common Stock | 0.014 | 0.014 | 0.014 | 0.014 | 0.014 |
| Additional Paid-In Capital | 281.067 | 278.88 | 276.827 | 274.783 | 272.749 |
| Retained Earnings (Accumulated Deficit) | -124.763 | -114.899 | -106.093 | -96.276 | -88.892 |
| Total Liabilities & Shareholders’ Equity | 161.378 | 170.548 | 177.17 | 184.305 | 191.682 |
| Total Common Shares Outstanding | 13.7568 | 14.3068 | 14.3068 | 14.3066 | 14.3066 |
| Total Preferred Shares Outstanding | 0.12417 | 0.11427 | 0.11427 | 0.11427 | 0.11427 |
| Other Liabilities, Total | 0.35 | 0.4 | 0.045 | 0.09 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netto indkomst/Startlinje | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
| Likvider Fra Driftsaktiviteter | -28.913 | -15.212 | -13.857 | -11.893 | -14.941 |
| Likvider Fra Driftsaktiviteter | 0 | 0.005 | 0.009 | 0.011 | 0.022 |
| Ikke-Likvide Ting | 8.099 | 8.178 | 3.348 | 1.543 | 0.628 |
| Ændringer i Driftskapital | -0.152 | -0.18 | -1.203 | 0.618 | -2.475 |
| Likvider fra Investeringsaktiviteter | 0 | 11.035 | 0 | 23.258 | |
| Kapitaludgifter | |||||
| Andre Investerings-Cash-Flow-Ting, Total | 0 | 11.035 | 0 | 23.258 | |
| Likvider fra Financieringsaktiviteter | -0.449 | 109.581 | 9.676 | 7.562 | 7.869 |
| Financiering af Cash-Flow-Ting | -0.45 | -0.025 | |||
| Udstedelse (Pensionering) af Aktier, Netto | 0.001 | 109.606 | 9.676 | 7.562 | 7.869 |
| Udstedelse (Pensionering) af Gæld, Netto | |||||
| Netto Ændring i Likviditet | -29.362 | 105.404 | -4.181 | -4.331 | 16.186 |
| Deferred Taxes | -2.354 | -0.404 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -9.864 | -34.506 | -25.7 | -15.883 | -8.499 |
| Cash From Operating Activities | -8.156 | -28.913 | -19.705 | -12.612 | -5.166 |
| Cash From Operating Activities | 0 | 0 | 0 | 0 | |
| Deferred Taxes | 0 | -2.354 | -1.775 | -1.089 | -0.501 |
| Non-Cash Items | 2.279 | 8.099 | 5.985 | 3.898 | 1.82 |
| Changes in Working Capital | -0.571 | -0.152 | 1.785 | 0.462 | 2.014 |
| Cash From Financing Activities | 0 | -0.449 | -0.449 | -0.45 | -0.45 |
| Financing Cash Flow Items | 0 | -0.45 | -0.45 | -0.45 | -0.45 |
| Issuance (Retirement) of Stock, Net | 0.001 | 0.001 | 0 | 0 | |
| Net Change in Cash | -8.156 | -29.362 | -20.154 | -13.062 | -5.616 |
| Cash From Investing Activities | 0 | 0 | |||
| Other Investing Cash Flow Items, Total | 0 | 0 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| BVF Partners L.P. | Hedge Fund | 16.9132 | 2326710 | 0 | 2022-12-31 | LOW |
| ALS Therapy Development Institute | Corporation | 9.6359 | 1325585 | 0 | 2022-03-31 | LOW |
| Cormorant Asset Management, LP | Hedge Fund | 8.853 | 1217882 | -5618 | 2022-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.9398 | 679557 | 314 | 2022-12-31 | LOW |
| Woodline Partners LP | Hedge Fund | 3.7558 | 516675 | 0 | 2022-12-31 | HIGH |
| Medical Strategy GmbH | Investment Advisor | 3.4338 | 472383 | 0 | 2022-09-30 | LOW |
| Ensign Peak Advisors, Inc. | Foundation | 3.2202 | 443001 | 355715 | 2022-12-31 | LOW |
| CM Management, LLC | Investment Advisor | 1.7068 | 234800 | -10200 | 2022-12-31 | MED |
| Ikarian Capital LLC | Hedge Fund | 1.6125 | 221830 | 0 | 2022-12-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9388 | 129151 | -314 | 2022-12-31 | LOW |
| ACCI Capital Investments SGIIC, SA | Investment Advisor | 0.4361 | 60000 | 0 | 2022-12-31 | LOW |
| JMAC Enterprises LLC | Investment Advisor | 0.3964 | 54538 | 0 | 2022-12-31 | LOW |
| Ingalls & Snyder LLC (Asset Management) | Investment Advisor/Hedge Fund | 0.3696 | 50849 | -300 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.3569 | 49095 | 532 | 2022-12-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 0.3434 | 47237 | -24700 | 2022-12-31 | HIGH |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3249 | 44692 | 0 | 2022-12-31 | LOW |
| SVB Financial Group | Holding Company | 0.2952 | 40613 | 40613 | 2022-12-31 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.2185 | 30053 | 0 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.2157 | 29673 | -2200 | 2022-12-31 | HIGH |
| Boothbay Fund Management, LLC | Investment Advisor/Hedge Fund | 0.1603 | 22050 | 0 | 2022-12-31 | HIGH |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Eledon Pharmaceuticals, Inc. Company profile
Om Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. er en biofarmaceutisk virksomhed i den kliniske fase. Virksomheden fokuserer på at udvikle lægemidler til personer, der lever med en autoimmun sygdom, som kræver en organ- eller cellebaseret transplantation, eller som lever med amyotrofisk lateralsklerose (ALS). Selskabets vigtigste produktkandidat, AT-1501, er et humaniseret monoklonalt antistof (mAb), der er designet til at angribe CD40-ligand (CD40L, også kaldet CD154), et molekyle, der udtrykkes på overfladen af menneskelige T-celler i immunsystemet. Den centrale rolle, som CD40- eller CD40L-signalering spiller i forbindelse med generering af proinflammatoriske reaktioner, gør det til en kandidat til terapeutisk intervention ved autoimmune sygdomme, induktion og vedligeholdelse af transplantationstolerance og neuroinflammation. Blokering af aktivering af CD40L-systemet forhindrer akut og langvarig afstødning af allografttransplantater i flere dyrearter og forbedrer sygdomsudvikling og patologi i prækliniske modeller af autoimmunitet og ALS.
| Industry: | Bio Therapeutic Drugs |
19900 MacArthur Blvd Ste 550
92612-8426
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com